DOH on alert as Sanofi admits dengue vaccine poses risks


MANILA – The manufacturer of the world’s first dengue vaccine has admitted the drug may be harmful when administered to individuals not previously infected with dengue.

Sanofi Pasteur said Wednesday it has a new analysis of long-term clinical trial data on dengue vaccine Dengvaxia.

“Dengvaxia provides persistent protective benefits against dengue fever in those who had prior infection. For those not previously infected by dengue virus, however…more cases of severe disease could occur following vaccination upon a subsequent dengue infection,” the statement read. Continue reading.